دورية أكاديمية
أعرض في EDS

Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy.

التفاصيل البيبلوغرافية
العنوان: Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy.
المؤلفون: Wątroba M; Laboratory of the Blood-Brain Barrier, Department of Biophysics, Physiology & Pathophysiology, Medical University of Warsaw, Chałubińskiego 5, 02-400 Warsaw, Poland., Grabowska AD; Laboratory of the Blood-Brain Barrier, Department of Biophysics, Physiology & Pathophysiology, Medical University of Warsaw, Chałubińskiego 5, 02-400 Warsaw, Poland., Szukiewicz D; Laboratory of the Blood-Brain Barrier, Department of Biophysics, Physiology & Pathophysiology, Medical University of Warsaw, Chałubińskiego 5, 02-400 Warsaw, Poland.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 09; Vol. 25 (14). Date of Electronic Publication: 2024 Jul 09.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Chemokine CX3CL1*/metabolism , Signal Transduction* , Microglia*/metabolism , Microglia*/pathology, Humans ; Animals ; CX3C Chemokine Receptor 1/metabolism
مستخلص: Diabetes mellitus (DM) is the most common metabolic disease in humans, and its prevalence is increasing worldwide in parallel with the obesity pandemic. A lack of insulin or insulin resistance, and consequently hyperglycemia, leads to many systemic disorders, among which diabetic encephalopathy (DE) is a long-term complication of the central nervous system (CNS), characterized by cognitive impairment and motor dysfunctions. The role of oxidative stress and neuroinflammation in the pathomechanism of DE has been proven. Fractalkine (CX3CL1) has unique properties as an adhesion molecule and chemoattractant, and by acting on its only receptor, CX3CR1, it regulates the activity of microglia in physiological states and neuroinflammation. Depending on the clinical context, CX3CL1-CX3CR1 signaling may have neuroprotective effects by inhibiting the inflammatory process in microglia or, conversely, maintaining/intensifying inflammation and neurotoxicity. This review discusses the evidence supporting that the CX3CL1-CX3CR1 pair is neuroprotective and other evidence that it is neurotoxic. Therefore, interrupting the vicious cycle within neuron-microglia interactions by promoting neuroprotective effects or inhibiting the neurotoxic effects of the CX3CL1-CX3CR1 signaling axis may be a therapeutic goal in DE by limiting the inflammatory response. However, the optimal approach to prevent DE is simply tight glycemic control, because the elimination of dysglycemic states in the CNS abolishes the fundamental mechanisms that induce this vicious cycle.
References: J Neurosci. 2012 May 9;32(19):6435-43. (PMID: 22573666)
J Neuroimmunol. 2002 Apr;125(1-2):59-65. (PMID: 11960641)
J Immunol. 2006 Dec 1;177(11):7599-606. (PMID: 17114429)
Brain. 2006 Nov;129(Pt 11):3006-19. (PMID: 16984903)
Pathobiology. 2010;77(1):7-16. (PMID: 20185962)
Neurosci Lett. 2008 May 9;436(2):196-200. (PMID: 18378084)
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8075-80. (PMID: 10869418)
Nature. 1997 Feb 13;385(6617):640-4. (PMID: 9024663)
Neuropathol Appl Neurobiol. 2013 Feb;39(1):19-34. (PMID: 23039106)
Diabetes Metab. 2009 Feb;35(1):12-9. (PMID: 19046917)
Nat Rev Neurol. 2012 Nov 5;8(11):647-56. (PMID: 23007702)
Acta Biochim Pol. 2023 Nov 22;70(4):751-760. (PMID: 37991083)
Science. 2011 Sep 9;333(6048):1456-8. (PMID: 21778362)
Brain Pathol. 2008 Apr;18(2):253-66. (PMID: 18363936)
Mol Neurobiol. 2024 Mar 14;:. (PMID: 38483656)
Stroke. 2011 Nov;42(11):3252-7. (PMID: 21852606)
Epilepsia. 2013 Oct;54(10):1834-44. (PMID: 24032743)
J Neuroinflammation. 2005 Jul 29;2:17. (PMID: 16053521)
Genetics. 2011 Sep;189(1):165-76. (PMID: 21750256)
Springer Semin Immunopathol. 2000;22(4):371-91. (PMID: 11155442)
J Clin Invest. 2003 Apr;111(8):1241-50. (PMID: 12697743)
Biomed Pharmacother. 2022 Jun;150:112933. (PMID: 35413600)
J Neurosci Res. 2004 Dec 15;78(6):880-91. (PMID: 15499593)
J Neuroinflammation. 2023 Mar 3;20(1):57. (PMID: 36869375)
J Cereb Blood Flow Metab. 2008 Oct;28(10):1707-21. (PMID: 18575457)
Cell Mol Immunol. 2018 Apr;15(4):324-334. (PMID: 29375126)
Eur J Pharmacol. 2011 Jul 1;661(1-3):15-21. (PMID: 21536024)
J Neurosci. 2016 Oct 26;36(43):11138-11150. (PMID: 27798193)
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6. (PMID: 18178625)
Cell Mol Immunol. 2023 Jul;20(7):739-776. (PMID: 37198402)
Annu Rev Immunol. 2009;27:119-45. (PMID: 19302036)
Neurobiol Aging. 2011 Nov;32(11):2030-44. (PMID: 20018408)
Front Aging Neurosci. 2017 May 03;9:118. (PMID: 28515688)
Adv Exp Med Biol. 2020;1231:1-12. (PMID: 32060841)
J Clin Med. 2023 Jul 21;12(14):. (PMID: 37510939)
Int J Alzheimers Dis. 2012;2012:685739. (PMID: 22645697)
J Immunol. 2008 Jun 1;180(11):7590-6. (PMID: 18490761)
Brain Commun. 2024 Mar 22;6(2):fcae079. (PMID: 38524154)
J Neuroimmunol. 2012 Apr;245(1-2):87-92. (PMID: 22261545)
J Biol Chem. 1999 Apr 9;274(15):10053-8. (PMID: 10187784)
Diabetes Metab. 2012 Apr;38(2):171-8. (PMID: 22349032)
Front Cell Neurosci. 2019 Sep 13;13:414. (PMID: 31607865)
J Clin Invest. 2007 Oct;117(10):2920-8. (PMID: 17909628)
J Diabetes Metab Disord. 2017 Apr 4;16:15. (PMID: 28396851)
J Neurosci. 2011 Nov 9;31(45):16327-35. (PMID: 22072684)
Drugs. 2012 Jan 1;72(1):49-66. (PMID: 22191795)
Cell. 2013 Apr 11;153(2):413-25. (PMID: 23582329)
Diabetes Care. 2017 Jan;40(1):136-154. (PMID: 27999003)
J Diabetes Complications. 2010 Sep-Oct;24(5):354-60. (PMID: 19748287)
Neurochem Int. 2020 Dec;141:104878. (PMID: 33049336)
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10896-901. (PMID: 9724801)
Neurosci Lett. 2018 Feb 5;665:67-73. (PMID: 29129676)
Lancet Diabetes Endocrinol. 2023 Oct;11(10):768-782. (PMID: 37708901)
Mol Pharmacol. 2006 Mar;69(3):857-65. (PMID: 16317113)
J Immunol. 1999 Aug 1;163(3):1628-35. (PMID: 10415068)
Anat Cell Biol. 2012 Mar;45(1):47-52. (PMID: 22536551)
Nature. 1997 Jun 5;387(6633):611-7. (PMID: 9177350)
J Neurosci. 2009 Feb 4;29(5):1319-30. (PMID: 19193879)
Ageing Res Rev. 2018 Mar;42:28-39. (PMID: 29247713)
Nature. 2001 Dec 13;414(6865):813-20. (PMID: 11742414)
Brain Res Bull. 2019 Mar;146:12-21. (PMID: 30496784)
PLoS Med. 2009 Jul;6(7):e1000113. (PMID: 19636355)
Int J Mol Sci. 2023 Jan 22;24(3):. (PMID: 36768537)
Rev Neurosci. 2007;18(2):137-48. (PMID: 17593876)
Brain Res. 2003 Jul 25;979(1-2):65-70. (PMID: 12850572)
Nat Neurosci. 2006 Jul;9(7):917-24. (PMID: 16732273)
Neuron. 2012 Sep 6;75(5):824-37. (PMID: 22958823)
Nat Rev Neurosci. 2004 Feb;5(2):146-56. (PMID: 14735117)
Nat Rev Endocrinol. 2015 Dec;11(12):701-11. (PMID: 26460339)
J Neuroimmunol. 2013 Apr 15;257(1-2):110-5. (PMID: 23499256)
Neurosci Lett. 2001 May 4;303(2):132-6. (PMID: 11311510)
Sci Rep. 2016 Aug 25;6:31895. (PMID: 27557632)
J Immunol. 2013 Aug 1;191(3):1063-72. (PMID: 23817416)
Neurobiol Aging. 1996 Jan-Feb;17(1):123-30. (PMID: 8786794)
Diabetes. 2015 Nov;64(11):3927-36. (PMID: 26216852)
J Neuroinflammation. 2013 Aug 27;10:108. (PMID: 23981568)
J Neurosci. 2000 Aug 1;20(15):RC87. (PMID: 10899174)
Nat Rev Neurosci. 2005 Jul;6(7):521-32. (PMID: 15995723)
Neural Regen Res. 2022 Aug;17(8):1652-1658. (PMID: 35017411)
Trends Neurosci. 2007 Nov;30(11):596-602. (PMID: 17950926)
Transplant Proc. 2012 May;44(4):1026-8. (PMID: 22564616)
J Neurochem. 2012 May;121(4):619-28. (PMID: 22260232)
Mol Neurobiol. 2007 Oct;36(2):137-51. (PMID: 17952658)
Circ Res. 2010 Oct 29;107(9):1058-70. (PMID: 21030723)
Brain Behav Immun. 2010 Oct;24(7):1190-201. (PMID: 20570721)
Trends Neurosci. 2005 Feb;28(2):101-7. (PMID: 15667933)
Nat Commun. 2019 Jul 12;10(1):3084. (PMID: 31300652)
J Neuroinflammation. 2011 Jan 25;8:9. (PMID: 21266082)
World J Clin Cases. 2023 Sep 6;11(25):5840-5856. (PMID: 37727490)
Nat Rev Neurosci. 2006 Aug;7(8):628-43. (PMID: 16858391)
Int J Mol Sci. 2023 Jun 13;24(12):. (PMID: 37373216)
J Neurochem. 2009 Sep;110(5):1547-56. (PMID: 19627440)
J Neuroinflammation. 2024 Feb 4;21(1):42. (PMID: 38311721)
Acta Neuropathol Commun. 2016 Sep 17;4(1):102. (PMID: 27639555)
J Cereb Blood Flow Metab. 2017 Jun;37(6):2249-2261. (PMID: 27488909)
Int J Mol Sci. 2021 Feb 05;22(4):. (PMID: 33562512)
Mediators Inflamm. 2019 Nov 12;2019:7570452. (PMID: 31780870)
Mol Neurobiol. 2024 Mar 13;:. (PMID: 38478143)
Front Neurol. 2021 Oct 28;12:766216. (PMID: 34777234)
Nat Rev Neurosci. 2011 Jun 15;12(7):388-99. (PMID: 21673720)
J Neuropathol Exp Neurol. 2003 Sep;62(9):899-907. (PMID: 14533779)
Nat Rev Neurosci. 2007 Nov;8(11):895-903. (PMID: 17948033)
BMJ Open. 2022 Nov 08;12(11):e060786. (PMID: 36351737)
J Neurosci. 2012 Oct 24;32(43):15106-11. (PMID: 23100431)
Front Neuroendocrinol. 2001 Jul;22(3):147-84. (PMID: 11456467)
Int J Mol Sci. 2024 Apr 15;25(8):. (PMID: 38673943)
BMJ. 2021 Jan 13;372:m4573. (PMID: 33441402)
J Neurosci. 2013 Jul 10;33(28):11556-72. (PMID: 23843525)
Exp Mol Med. 2004 Oct 31;36(5):461-7. (PMID: 15557818)
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14500-5. (PMID: 9826729)
Nat Neurosci. 2006 Jul;9(7):859-61. (PMID: 16801915)
J Neurosci Res. 2016 Sep;94(9):781-93. (PMID: 27302739)
J Leukoc Biol. 2009 Mar;85(3):352-70. (PMID: 19028958)
Diabetologia. 2019 Jan;62(1):3-16. (PMID: 30171279)
Brain Res Rev. 2007 Feb;53(2):344-54. (PMID: 17188751)
Br J Pharmacol. 2011 Oct;164(4):1079-106. (PMID: 21371012)
Nat Neurosci. 2005 Jun;8(6):752-8. (PMID: 15895084)
FEBS J. 2018 Aug;285(16):2944-2971. (PMID: 29637711)
Redox Biol. 2024 Feb;69:102996. (PMID: 38103341)
Med Sci Monit. 2018 Dec 05;24:8804-8811. (PMID: 30517088)
Int J Mol Sci. 2023 Jan 07;24(2):. (PMID: 36674713)
Front Immunol. 2022 Feb 08;13:705852. (PMID: 35211112)
J Neuroimmunol. 2005 Sep;166(1-2):19-28. (PMID: 16019082)
Curr Pain Headache Rep. 2024 Jun;28(6):481-487. (PMID: 38558164)
Neuroendocrinology. 2007;86(2):136-42. (PMID: 17643054)
J Biol Chem. 2008 Oct 31;283(44):30225-34. (PMID: 18725411)
Peptides. 2007 May;28(5):1029-34. (PMID: 17360072)
Neuroscience. 2012 Dec 6;225:162-71. (PMID: 22824429)
J Pharmacovigil. 2014 Jun;2(2):125. (PMID: 25632404)
Curr Protein Pept Sci. 2019;20(8):844-854. (PMID: 30843484)
Gastroenterology. 2007 May;132(6):2169-80. (PMID: 17498510)
Int J Mol Sci. 2018 Jan 22;19(1):. (PMID: 29361745)
Eur J Neurosci. 2004 Dec;20(12):3222-32. (PMID: 15610155)
Front Immunol. 2021 May 13;12:622438. (PMID: 34054797)
Front Immunol. 2022 Feb 15;12:690082. (PMID: 35242125)
Glia. 2000 Feb 15;29(4):305-15. (PMID: 10652441)
Neurology. 2003 Jun 24;60(12):1899-903. (PMID: 12821730)
Annu Rev Biochem. 2018 Jun 20;87:897-919. (PMID: 29925258)
J Cereb Blood Flow Metab. 2019 May;39(5):808-821. (PMID: 29047291)
J Biol Chem. 2011 Mar 18;286(11):9856-64. (PMID: 21245135)
J Neuroimmunol. 2009 Oct 30;215(1-2):36-42. (PMID: 19709758)
Neurochem Int. 2013 Oct;63(4):331-43. (PMID: 23876631)
Front Cell Neurosci. 2018 Oct 02;12:329. (PMID: 30333729)
Int J Mol Sci. 2024 Apr 25;25(9):. (PMID: 38731899)
Science. 2005 May 27;308(5726):1314-8. (PMID: 15831717)
Mediators Inflamm. 2013;2013:480739. (PMID: 23997430)
PLoS Comput Biol. 2021 May 20;17(5):e1008593. (PMID: 34014914)
Int Immunopharmacol. 2019 Feb;67:294-301. (PMID: 30572254)
Cerebellum. 2023 Nov 10;:. (PMID: 37950146)
Rev Neurosci. 2015;26(6):691-8. (PMID: 26226128)
Cell Rep. 2017 Oct 31;21(5):1129-1139. (PMID: 29091753)
Neural Plast. 2015;2015:689404. (PMID: 26347402)
J Biol Chem. 2005 Dec 2;280(48):40364-74. (PMID: 16183991)
Heliyon. 2022 Aug 03;8(8):e10073. (PMID: 35991978)
FASEB J. 2004 Aug;18(11):1297-9. (PMID: 15208270)
فهرسة مساهمة: Keywords: CX3CL1/CX3CR1 axis; advanced glycation end products; central nervous system; chemokine CX3CL1; diabetes mellitus; diabetic encephalopathy; fractalkine; hyperglycemia; neuroinflammation
المشرفين على المادة: 0 (Chemokine CX3CL1)
0 (CX3C Chemokine Receptor 1)
0 (CX3CL1 protein, human)
تواريخ الأحداث: Date Created: 20240727 Date Completed: 20240728 Latest Revision: 20240814
رمز التحديث: 20240814
مُعرف محوري في PubMed: PMC11277241
DOI: 10.3390/ijms25147527
PMID: 39062768
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25147527